NDAORALTABLET
Approved
Nov 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 4h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUTAB is an oral tablet formulation of sodium sulfate, magnesium sulfate, and potassium chloride—a bowel prep agent indicated for colonoscopy preparation. It works by osmotically drawing fluid into the colon to cleanse the bowel, enabling safe visualization of the intestinal tract. The tablet form offers a more convenient alternative to liquid preparations.
$0.029BPart D
Peak11.0 years to LOEPeak-stage product with $29M in Part D spending indicates stable market penetration; commercial team likely focused on maintaining share in a maturing bowel prep category with limited growth drivers.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SUTAB is a niche, peak-stage product in the bowel prep category with limited active job openings currently, reflecting its mature commercial profile. Career value lies in specialized expertise in GI/gastroenterology markets and experience managing stable, mature products—not high-growth innovation.
Brand ManagerField Sales Representative
Worked on SUTAB at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.